임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-05-28 12:55
논문번호 214
논문제목(영문) Improvement in Left Ventricular Function with Intracoronary Mesenchymal Stem Cell Therapy in a Patient with Anterior Wall ST-Segment Elevation Myocardial Infarction
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Su Hyun Kim
교신저자명 Jang Hyun Cho
공동저자명 Yoon Ho Lee , Ji Hye Lee,Soo, Sung Kim, Mi Yang Kim, Min Gu Lee, Won Yu Kang,Kyung Sim Lee, Young Keun Ahn, Myung Ho Jeong,Hyun Soo Kim
게제년월일 2018-06-28
ISSN 0920-3206
Impact Factor 4.069
학술지명 Cardiovascular Drugs and Therapy
서지사항 0집 / 32권 / 4호,   페이지(329 - 338)
요약초록문
(Abstract) 입력		 Background/aims: The progression and development of congestive heart failure is still considered a large problem despite the existence of revascularization therapies and optimal, state-of-the-art medical services. An acute myocardial infarction (AMI) is a major cause of congestive heart failure, so researchers are investigating techniques to complement primary percutaneous coronary intervention (PCI) or thrombolytic therapy to prevent congestive heart failure after AMI.

Methods: Twenty-six patients with successful PCI for acute ST-segment elevation anterior wall myocardial infarction were assigned to either a control group (n = 12) or a bone marrow mesenchymal stem cells (BM-MSC) group (n = 14). The control group received optimum post-infarction treatment, and the BMSC group received intracoronary delivery of autologous BMSC at 1 month after PCI with the optimum medical treatment. The primary endpoint was a left ventricular ejection fraction (LVEF) change from baseline to 4-month follow-up, as determined via myocardial single-photon emission computed tomography (SPECT).

Results: The global LVEF at baseline (determined 3.5 ± 1.5 days after PCI) was 35.4 ± 3.0% in the control group and 33.6 ± 4.7% in the BM-MSC group. BMSC transfer enhanced left ventricular systolic function primarily in anterior wall myocardial segments adjacent to the LAD infarcted area. Four months later, via SPECT, global LVEF had increased by 4.8 ± 1.9% in the control group and 8.8 ± 2.9% in the BM-MSC group (p = 0.031). The cell transfer did not increase the risk of adverse clinical events, in-stent restenosis, or proarrhythmic effects. The echocardiographic evaluation also revealed a significant increase in the LVEF value from baseline to the 4-month (9.0 ± 4.7 and 5.3 ± 2.6%, p = 0.023) and 12-month (9.9 ± 5.2% and 6.5 ± 2.7%, p = 0.048) follow-up in the BM-MSC group but not in the control group.

Conclusions: Intracoronary administration of autologous BM-MSC was tolerable and safe with significant improvement in LVEF at 4-month (SPECT and echocardiography result) and 12-month (echocardiography result only) follow-up in patients with anterior AMI.
파일  C214. Improvement in Left Ventricular Function with Intracoronary Mesenchym~.pdf (3.6M) DATE : 2021-05-28 12:55:54